Inflammatory Breast Neoplasms

SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in breast cancer using Myriad’s Precise ® MRD test. Research collaborations include: A study to determine whether circulating tumor DNA (ctDNA) level may predict magnitude of response to pembrolizumab and hormonal therapy in patients with HR-positive inflammatory breast cancer who did not achieve pathological complete response at the time of surgery, led by Bora Lim, MD, at The University of Texas MD Anderson Cancer Center. A study to evaluate whether ctDNA levels correlate with nodal involvement in patients with newly diagnosed HR-positive breast cancer and, if so, how the correspondence may be used to aid in surgical decision making, led by Anna Weiss, MD, at The University of Rochester Medical Center. The multicenter, prospective MONITOR-breast study to determine the association of ctDNA levels to both neoadjuvant and adjuvant therapy in patients with newly diagnosed breast cancer across all subtypes. The study will involve 650 patients and will assess the prognostic potential of ctDNA and the lead time of detecting recurrence earlier ahead of standard-of-care imaging. The multicenter, prospective study JBCRG-C11 (CREA) to evaluate the maintenance of complete response with trastuzumab deruxtecan (T-DXd) in HER2-positive advanced or metastatic breast cancer patients and whether ctDNA can be used to optimally guide therapy, led by Yoichi Naito, MD, of the National Cancer Center Hospital East in Japan. A study in partnership with Aptitude Health to assess ctDNA levels in high-risk patients at diagnosis, during neoadjuvant treatment, and following surgery in community oncology settings. “Relative to many other cancer types that typically have high levels of ctDNA in the blood, breast cancer often has very low levels of ctDNA, which makes MRD testing a challenge,” said Dale Muzzey, chief scientific officer, Myriad Genetics. “Myriad’s Precise MRD test is well suited to overcome this challenge because it tracks up to 1,000 tumor-specific variants identified via whole-genome sequencing. The research efforts we’re undertaking with leading organizations and investigators are an important step in advancing the clinical application of next-generation MRD testing to the treatment and monitoring of breast cancer.” Myriad continues to develop its Precise MRD test to meet the needs of cancer patients, academic partners, and biopharma companies. Myriad has previously announced other MRD collaborations, including a metastatic breast cancer study with researchers at Memorial Sloan Kettering Cancer Center and a prospective pan-cancer study, including breast cancer, led by researchers at the National Cancer Center Hospital East in Japan. About Myriad’s Precise MRD Test Myriad’s Precise MRD test is a tumor-informed, whole genome sequencing (WGS) based test that monitors hundreds to thousands of tumor-specific variants, which enables exceptional sensitivity and quantification of circulating tumor DNA (ctDNA) in the blood of patients with cancer. The Precise MRD test can be used to monitor ctDNA levels throughout a cancer patient’s clinical care, starting immediately after diagnosis and continuing through treatment and surveillance. The Precise MRD test is available for use in research studies pursued jointly by Myriad and academic or pharmaceutical investigators. About Myriad Genetics Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit . Myriad Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company’s research collaborations, such as a study that will involve 650 patients and will assess the prognostic potential of ctDNA and the lead time of detecting recurrence ahead of standard-of-care imaging, represent an important step in advancing the clinical application of next-generation MRD testing to the treatment and monitoring of breast cancer and that the company’s Precise MRD test is well suited to overcome some of the challenges faced by MRD testing because it tracks up to 1,000 tumor-specific variants identified via whole-genome sequencing. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. Investor Contact Matt Scalo (801) 584-3532 IR@myriad.com Media Contact Glenn Farrell (385) 318-3718 PR@myriad.com

KING OF PRUSSIA, Pa., Aug. 12, 2024 /PRNewswire/ -- The Association for Frontotemporal Degeneration (AFTD) announced Monday that the Milburn Foundation, a private charitable organization, provided a $25,000 challenge match for their "Empowered Together to #EndFTD" campaign. The campaign more than doubled its goal, securing the match and raising $75,000 to support AFTD's mission to improve the quality of life of people affected by frontotemporal dementia (FTD) and driving research to a cure. "We are deeply grateful to the Milburn Foundation for their support of AFTD's mission and this campaign," said AFTD CEO Susan Dickinson. "These funds will directly support families and individuals facing a diagnosis, and will help educate healthcare professionals and policymakers so that we can develop earlier and more accurate diagnosis and better care services." The Milburn Foundation is a private foundation that structures strategic partnerships with public charities to drive philanthropic innovation for both Frontotemporal Degeneration and Inflammatory Breast Cancer. "Families facing FTD, much like families facing breast cancer, urgently need access to viable treatments and a cure," said Milburn Foundation CEO Bryon Davis. "Our gift to AFTD embodies our commitment to true partnership and collaboration in the field of disease research. The Milburn Foundation shares AFTD's mission to hasten a future without FTD, and we hope these funds can contribute to the FTD-free world sought by both our organizations." AFTD works every day to empower the FTD community by supporting persons diagnosed, care partners, and families at every stage of the FTD journey, and taking action to educate others, advance research, and raise vital awareness. The campaign featured six personal stories from the FTD community, including caregivers and family members, across print and digital channels. Channing Clifford, who has a popular TikTok channel where she connects with families on the FTD journey, was featured in the campaign. "Any time I have knowledge of what to do next, it's because of AFTD. It's empowering to know that this organization not only offers support for the tough parts of this diagnosis, but also communicates with people affected," she said. FTD is a neurodegenerative disorder that causes the gradual breakdown of nerve cells in the frontal and temporal lobes of the brain. The progression of the disease can lead to significant disability over time, including extreme changes in personality, behavior, language, and motor skills that can impact daily functioning and require around-the-clock care and support. FTD typically strikes individuals between the ages of 40 and 65, but it can also occur in both older and younger individuals. On average, it takes nearly four years for a person to receive an accurate FTD diagnosis as symptoms are often misdiagnosed as a psychiatric condition, Alzheimer's disease, or Parkinson's disease. This delay is often due to the medical community's lack of familiarity with FTD. Delays in diagnosis can also cause devastating financial hardships for families, with the economic burden of FTD being almost twice that of Alzheimer's disease, as individuals impacted are often compelled to leave the workforce during peak earning years. To learn more about AFTD and its work, go to . About AFTD AFTD is the leading organization focused on helping people and families impacted by FTD, and driving research for a cure. Our organization is committed to facilitating and funding FTD-focused research that can hold the key to ensuring more accurate diagnosis, prevention, treatments, and a cure, with implications for other forms of dementia and related neurodegenerative diseases. About the Milburn Foundation The Milburn Foundation, an award-winning philanthropic partner to public charities, funds critical disease research and creates grant agreements to unite organizations with shared causes. Since 2007, we've catalyzed collaboration among research institutions, public charities, and patient advocates to explore, publish, and validate solutions to persistent research challenges. Additionally, we've helped raise millions of dollars through innovative fundraising approaches, such as challenge-matching grants. Contacts: Cristian Salazar The Lead PR 929-584-8731 or [email protected] SOURCE The Association For Frontotemporal Degeneration

NORTH CHICAGO, Ill., June 4, 2024 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science research faculty have been named among "Illinois Researchers to Know" by the Illinois Science and Technology Coalition. The annual list recognizes the groundbreaking work of scientists and ten institutions driving innovation in the state. The three Rosalind Franklin researchers are: Brian Feinstein, PhD, associate professor in the Department of Psychology and director of the Sexuality, Health and Gender Lab at RFU. Dr. Feinstein's research areas include sexual and gender minority (SGM) health, stigma-related stress and coping, bisexuality and pansexuality and mental health, substance use, sexual health, and relationship functioning in SGM populations, and developing and testing interventions to improve SGM health. Robert Marr, PhD, associate professor, Center for Neurodegenerative Diseases and Therapeutics, and Chicago Medical School assistant dean for research. Dr. Marr studies neurodegenerative diseases, with a focus on Alzheimer's disease (AD), including the use of gene transfer vectors as a tool to investigate specific gene function(s) in the brain as it relates to AD, the derivation of potentially new therapeutic approaches to AD, and the role of Alzheimer's related genes in the process of traumatic brain injury. Neelam Sharma-Walia, PhD, associate professor, Center for Cancer Cell Biology, Immunology and Infection. Dr. Sharma-Walia's research has principally focused on oncolytic viruses and cancer. Her lab also works to understand the role of arachidonic acid metabolism and the complexity of the tumor microenvironment in the biology of inflammatory breast cancer, the most aggressive, highly metastatic form of breast cancer. RFU Executive Vice President for Research Dr. Ronald Kaplan thanked the ISTC for spotlighting how investments in academic research and scientific discovery are driving innovation and improving human health. "We are pleased by the inclusion of RFU scientists in this prestigious list," Dr. Kaplan said. "Dr. Feinstein, Dr. Marr and Dr. Sharma-Walia have made significant contributions, particularly in the last 12 months, in key diseases or health conditions that impact both U.S. and international populations. About Rosalind Franklin University Recognized for its research in areas including neuroscience, brain-related diseases, inherited disorders, diabetes, obesity, and gait and balance, RFU encompasses the Chicago Medical School, College of Health Professions, College of Nursing, College of Pharmacy, Dr. William M. Scholl College of Podiatric Medicine, and School of Graduate and Postdoctoral Studies. Learn more at rosalindfranklin.edu. Contact: Office of Marketing and Communications, [email protected] SOURCE Rosalind Franklin University of Medicine and Science